Tag: form

Paris, 4 July 2025

Las Vegas, NV, July 03, 2025 (GLOBE NEWSWIRE) -- Area 52, a vanguard in cannabinoid science and botanical engineering, today announced the debut of its 2025 THCA Snow Caps collection, a groundbreaking line of premium hemp flower completely enveloped in pure THCA diamonds. Engineered to “Alienize Your Mind,” these crystalline-coated buds represent a new frontier in potency and sensory experience for the discerning cannabis connoisseur.

Honest Loans offers access to flexible online loan connections in 2025, supporting fast funding options for borrowers with less-than-perfect credit.

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against KBR, Inc. (“KBR” or the “Company”) (NYSE:KBR) on behalf of KBR stockholders. Our investigation concerns whether KBR has violated the federal securities laws and/or engaged in other unlawful business practices.

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

Binaural beat-based audio suite supports focus, rest, and digital clarity with a non-invasive, non-clinical format—now updated for 2025.

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.